Category
XANTHINE OXIDASE INHIBITORS
XANTHINE OXIDASE INHIBITORS
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Febuxostat API has been developed by ASANA Pharmaceutical as part of its metabolic and anti-gout therapeutic range. Febuxostat API, listed under CAS number 144060-53-7, is a non-purine selective xanthine oxidase inhibitor used to lower uric acid levels in patients with chronic gout and hyperuricemia.
ASANA Pharmaceutical brings expertise in the development and manufacturing of xanthine oxidase inhibitors such as Febuxostat, an API known for its role in managing chronic hyperuricemia. With a commitment to regulatory precision and pharmaceutical innovation, ASANA serves clients across North America, Europe, and Asia. Our facilities and quality systems are designed for high-compliance production and dependable global supply
ASANA Pharmaceutical collaborates closely with leading R&D labs and formulation teams to optimize synthesis pathways, purification processes, and documentation support for APIs like Febuxostat. Backed by a specialized portfolio focused on anti-gout and urate-lowering therapies, ASANA meets increasing demand in rheumatology and metabolic care. We continue to support pharmaceutical partners with:
Febuxostat API are available on public databases such as Wikipedia. Wikipidia!